Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Keen Vision Acquisition Corp. - KVAC
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation